中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

158 records (took 0.019 seconds)

    BISPECIFIC ANTIBODIES BINDING TO COAGULATION FACTOR IX AND COAGULATION FACTOR X
    131.
    发明公开
    BISPECIFIC ANTIBODIES BINDING TO COAGULATION FACTOR IX AND COAGULATION FACTOR X 审中-公开

    公开(公告)号：US20230192896A1

    公开(公告)日：2023-06-22

    申请号：US16462878

    申请日：2017-11-22

    Applicant: Bioverativ Therapeutics Inc.

    Inventor： Robert T. PETERS ,  Nina LEKSA ,  Bradley R. PEARSE ,  John KULMAN ,  Maria ALEMAN ,  Allison GOODMAN

    IPC: C07K16/46 ,  A61P7/04

    CPC classification number: C07K16/468 ,  A61P7/04 ,  C07K2317/565 ,  C07K2317/31 ,  C07K2317/34

    Abstract: The present disclosure provides antibodies that selectively binds to specific forms of clotting factors, in particular, antibodies that specifically binds to activated factor IX (FIXa) wherein the anti-FIXa antibody or an antigen binding portion thereof preferentially binds to FIXa in the presence of FIXa and factor IX zymogen (FIXz), and antibodies that specifically bind to factor X zymogen (FXz) wherein the anti-FXz antibody or antigen binding portion thereof preferentially binds to FXz in the presence of FXz and activated factor X (FXa). Also provided are bispecific molecules (e.g., antibodies) comprising, e.g., an anti-FIXa antibody or antigen binding portion thereof and/or an anti-FXz antibody or antigen binding portion thereof. The disclosure also provides compositions encoding the disclosed antibodies and bispecific molecules, vectors, cells, pharmaceutical and diagnostic compositions, kits, methods of manufacture, methods of use, and immunoconjugates.

    CHIMERIC CLOTTING FACTORS
    135.
    发明申请
    CHIMERIC CLOTTING FACTORS 有权

    公开(公告)号：US20220135959A1

    公开(公告)日：2022-05-05

    申请号：US17496092

    申请日：2021-10-07

    Applicant: Bioverativ Therapeutics Inc.

    Inventor： Joe SALAS ,  Elena KISTANOVA ,  Vu Phong HONG ,  Adam R. MEZO ,  Robert T. PETERS

    IPC: C12N9/64 ,  A61K38/48 ,  A61K47/62 ,  A61K38/36

    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.

    Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
    138.
    发明授权
    Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof 有权

    公开(公告)号：US11091534B2

    公开(公告)日：2021-08-17

    申请号：US16154310

    申请日：2018-10-08

    Applicant: Bioverativ Therapeutics Inc.

    Inventor： Ekta Seth Chhabra ,  Tongyao Liu ,  Pei-yun Chang ,  Robert T. Peters ,  John Kulman ,  Haiyan Jiang

    IPC: C07K14/755 ,  A61K47/55 ,  A61K38/36 ,  A61K38/37 ,  C07K16/00 ,  C12N15/11

    Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.

    Optimized factor IX gene
    139.
    发明授权
    Optimized factor IX gene 有权

    公开(公告)号：US11008561B2

    公开(公告)日：2021-05-18

    申请号：US15323302

    申请日：2015-06-30

    Applicant: BIOVERATIV THERAPEUTICS INC.

    Inventor： Siyuan Tan ,  Robert T. Peters ,  Tongyao Liu

    IPC: C07K14/745 ,  C07K14/755 ,  A61K48/00 ,  C12N9/64

    Abstract: The present invention provides codon optimized Factor IX sequences, vectors and host cells comprising codon optimized Factor IX sequences, polypeptides encoded by codon optimized Factor IX sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor IX nucleic acid sequence or the polypeptide encoded thereby.

Patent Agency Ranking